DLBCL
Roche unveils its blood cancer strategy after COVID-19 boost
While Roche has seen a decline in COVID-19 drug sales after the pandemic boom, the company is experiencing a resurgence ...
Unveiling 2023’s Drug Approvals: Beyond Oncology Boundaries
In the ever-evolving realm of oncology of 2023 emerges as a pivotal era characterized by a wave of significant approvals ...
EMA Accepts Filing for Odronextamab to Address Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Regeneron Pharmaceuticals achieved a significant milestone with the European Medicines Agency (EMA) accepting the Marketing Authorization Application (MAA) for odronextamab, ...
AbbVie’s Epcoritamab (EPKINLY) Receives Positive CHMP Opinion for DLBCL Treatment
Source – AbbVieAbbVie and Genmab’s potential blockbuster drug epcoritamab has received a favorable recommendation for conditional approval in the EU ...
Discontinuation of LOTIS-9 Trial: Zynlonta in Unfit DLBCL Patients
Source – ADC Therapeutics On July 20, 2023, ADC Therapeutics announced its decision to discontinue the Phase II LOTIS-9 clinical ...
After 7 patient fatalities and 5 other serious adverse events, ADC suspends the Zynlonta research
Source – ADC Therapeutics ADC Therapeutics has halted enrollment in a Phase II combination trial for Zynlonta following the investigation ...
Roche’s Columvi (glofitamab) for patients with R/R diffuse large B-cell lymphoma has received approval from the European Commission
Source – Roche On 11 July 2023 Roche announced that the European Commission (EC) has given conditional approval for Columvi ...
Roche’s Columvi and AbbVie’s Epkinly: The Battle for Breakthroughs in Large b Cell Lymphoma Treatment
Roche’s Columvi (glofitamab) receives FDA accelerated approval for treatment of Large b Cell Lymphoma, sparking a rivalry with AbbVie and ...
Glofitamab-gxbm receives FDA approval for relapsing or resistant DLBCL
Source – Roche Columvi (Glofitamab-gxbm) has been given expedited clearance by the FDA for the treatment of adult patients with ...
Epkinly: FDA-Approved Bispecific Antibody for DLBCL
On May 19, 2023, AbbVie announced that the U.S. Food and Drug Administration (FDA) granted approval to EPKINLYTM (epcoritamab-bysp) as ...
EPCORITAMAB RECEIVES FDA APPROVAL FOR RELAPSED/REFRACTORY DLBCL
The FDA has granted approval to epcoritamab-bysp (Epkinly), the first T-cell–engaging bispecific antibody, for the treatment of relapsed/refractory diffuse large ...
